874339-83-0

Basic information

• Product Name: 3-Pyridinecarboxylic acid, (2S)-6-[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[[4-[[(1,1-dimethylethoxy )carbonyl]amino]phenyl]sulfonyl](2-methylpropyl)amino]hexyl ester
• CAS NO: 874339-83-0
• Molecular Formula: C32H48N4O8S
• Molecular Weight: 648.821
• Mol File: 874339-83-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-Pyridinecarboxylic acid, (2S)-6-[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[[4-[[(1,1-dimethylethoxy )carbonyl]amino]phenyl]sulfonyl](2-methylpropyl)amino]hexyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarboxylic acid, (2S)-6-[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[[4-[[(1,1-dimethylethoxy )carbonyl]amino]phenyl]sulfonyl](2-methylpropyl)amino]hexyl ester(874339-83-0)
• EPA Substance Registry System: 3-Pyridinecarboxylic acid, (2S)-6-[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[[4-[[(1,1-dimethylethoxy )carbonyl]amino]phenyl]sulfonyl](2-methylpropyl)amino]hexyl ester(874339-83-0)

Safety Data

• Hazardous Substances Data: 874339-83-0(Hazardous Substances Data)

Upstream product

• 900187-22-6 (1-S)-{4-[(5-tert-butoxycarbonylamino-1-hydroxymethyl-pentyl)-isobutyl-sulfamoyl]-phenyl}-carbamic acid tert-butyl ester 
• 59-67-6 nicotinic acid 

Downstream Products

• 874339-84-1 (2S)-nicotinic acid 6-amino-2-[(4-amino-benzenesulfonyl)-isobutyl-amino]-hexyl ester 

Relevant articles and documents

LYSINE BASED COMPOUNDS

The present invention provides lysine based compounds of the formula (I); and when the compound of formula (I) comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein Rl may be, for example, (HO)2P(O)-, (NaO)2P(O)-, alkyl-CO- or cycloalkyl-CO-, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein. These lysine based compounds have a physiologically cleavable unit, namely R1 , whereby upon cleavage of the unit, an HIV aspartyl protease inhibitor is released,

METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS

The present invention provides methods for improving the pharmacokinetics of protease inhibitors and protease inhibitor precursors and pharmaceutical composition comprising protease inhibitors or protease inhibitor precursors of formula I and a cytochrome P450 monooxigenase inhibitor; Formula (I) when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1 may be, for example, (HO)2P(O)-, (NaO)2P(O)-, alkyl- CO- or cycloalkyl-CO-, wherein X may be, for example, F, CI, and Br, and wherein R2 and R3 are as defined herein.